[서울경제TV=김혜영기자]3bix, a company specializing in bio big data platforms, and the research team of Professor Seung-Hyun Han of Seoul National University’s School of Dentistry announced on the 9th that they had published a paper on the growth inhibition of resistant Staphylococcus aureus methicillin in Frontiers in Microbiology (SE: 6.064).
3bix and the research team intensively analyzed the growth inhibiting factors of methicillin-resistant Staphylococcus aureus through Next Generation Sequencing (NGS) and transcriptome analysis.
Microorganisms living in the human intestine decompose dietary fiber to produce short-chain fatty acids, which are an energy source for intestinal mucosal epithelial cells and play a role in maintaining health through antibacterial action and immune regulation . Propionate, one of the short fatty acids, can suppress MRSA and has been confirmed to have a calming effect that prevents bacteria from multiplying by targeting genes in major metabolic pathways, the company explained.
“Existing antibiotic treatments have low tissue uptake, slow bactericidal efficacy, and are difficult to control antibiotic-resistant bacteria such as MRSA, which has limitations in treating Staphylococcus aureus infections,” said Park Joon-hyeong, CEO of 3bix. MRSA metabolic pathway, weakens the growth of MRSA and can be used as a newly developed bacteriostatic agent which is biocompatible and less likely to induce resistance for the prevention and treatment of MRSA infectious diseases.
Meanwhile, Staphylococcus aureus (S. aureus) is a causative agent of various diseases such as pneumonia, gastroenteritis, endocarditis and septic shock. Among them, methicillin-resistant Staphylococcus aureus (MRSA) is a representative antibiotic-resistant Staphylococcus aureus. Infectious diseases caused by this bacterium show high morbidity and mortality worldwide, and the company explained that it is gradually increasing. /[email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >